- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06034834
Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries (IMPACT)
To date, intraoperative assessment of tissue and bone viability is predominantly subjective, depending on the clinical view of the surgeon, resulting in a variation in the thoroughness of debridement. Inadequate initial resection leads to multiple debridement interventions, leading to prolonged hospitalization or readmission with consequently high direct medical costs.
Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) could potentially be a relevant contribution to adequately treating soft tissue and skeletal injuries by creating an improved distinction between viable and non-viable tissue, based on perfusion indices.
This study evaluates whether intraoperative perfusion assessment with ICG fluorescence imaging is a feasible and quantifiable technique for treating traumatic injuries.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: In 2020 71.623 Dutch patients were acutely admitted to hospitals due to sustained traumatic injuries. 7% of the injuries related to open wounds and 44% to fractures. The majority of traumatic musculoskeletal injuries needs to be diagnosed and treated as soon as possible to lower the risk of infections and to minimize adverse outcome, such as necrosis and/or osteomyelitis. To date, intraoperative assessment of tissue and bone viability is predominantly subjective, resulting in a variation in thoroughness of debridement. If not all necrotic tissue is removed, suboptimal healing occurs, which serves as a potential food source for bacteria. In addition, inadequate initial resection leads to multiple debridement interventions, leading to prolonged hospitalization or readmission with consequently high direct medical costs. Since tissue necrosis is an ongoing process, radical resection of avital tissue during the initial procedure is not always possible. The surgeon's visual estimation is not optimal to predict the final amount of debridement. After maximal debridement, antibiotic treatment and coverage of open wounds, the incidence of infection can rise to 27%. Compromised perfusion is at the centre of this problem. An adequate blood supply is crucial for tissue viability and infection clearance.
Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) has already shown its potential in effective real-time assessment of intra-operative tissue perfusion and the early prediction of future necrosis in multiple studies. This technique could potentially be a relevant contribution in adequately treating soft tissue and skeletal injuries by creating an improved distinction between viable and non-viable tissue, based on perfusion indices. However to date, the feasibility to quantify this technique in posttraumatic tissue has not been successfully evaluated.
Objective: The primary objective of this study is to evaluate the feasibility of Near-infrared Fluorescence (NIRF) imaging with Indocyanine green (ICG) to assess and quantify tissue perfusion in post-traumatic soft tissue and/or skeletal injury.
Study design: The study is a prospective observational multicentre pilot study. All included patients will undergo a perfusion assessment using ICG NIR fluorescence imaging. Perfusion assessment will not affect treatment of patients.
Study population: Patients aged 18 years or older with traumatic soft tissue and/or skeletal injury. Injuries included in the study are: open deglovement; crush injuries of extremities; open fractures, non-unions of clavicula, tibia, humerus, rib and/or ulna fractures and fracture related infections.
Intervention: Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
Main study parameters/endpoints: The primary outcome of this study is a time-intensity curve with quantified perfusion parameters in traumatic soft tissue and/or skeletal injuries. Perfusion parameters included in the analyses are time till maximum intensity (Tmax), maximum intensity (Imax) the ingress rate, the normalized slope, the absolute slope and the area under the curve at 30, 60 and 120 seconds.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joost R van der Vorst, MD, PhD
- Phone Number: +31715298528
- Email: j.r.van_der_vorst@lumc.nl
Study Contact Backup
- Name: Inger B Schipper, Prof. MD, PhD
- Phone Number: +31715265025
- Email: i.b.schipper@lumc.nl
Study Locations
-
-
Zuid-Holland
-
Leiden, Zuid-Holland, Netherlands, 2333ZA
- Recruiting
- Leiden University Medical Center
-
Contact:
- Inger B Schipper, Prof. MD, PhD
- Phone Number: +31715265025
- Email: i.b.schipper@lumc.nl
-
Contact:
- Joost R van der Vorst, MD, PhD
- Phone Number: +3175298528
- Email: j.r.van_der_vorst@lumc.nl
-
Sub-Investigator:
- Stefan Koning, MD
-
Rotterdam, Zuid-Holland, Netherlands, 3000 CA
- Recruiting
- Erasmus University Medical Center
-
Contact:
- Mathieu M.E. Wijffels, MD, PhD
- Phone Number: +3107032395
- Email: m.wijffels@erasmusmc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
In order to be eligible to participate in this study, a subject must meet all the following criteria:
- Age ≥ 18 years
Diagnosed with one or more of the following injuries:
- Crush injury
- Open deglovement
- Open fracture(s) (Gustilo 3, -A, -B & -C)
- Non-union tibia/clavicula/ulna/humerus/rib
- Fracture related infection
- Indication for surgical intervention
Exclusion Criteria:
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Hemodynamically unstable due to severe blood loss
- Allergic or hypersensitive to iodine/crustaceans/shellfish
- Diagnosed with endocrine thyroid disorders (hyperthyroidism)
- Pregnancy
- Diagnosed with impaired renal function eGFR <30 L/min/1.73m2
- Diagnosed with severely disturbed hepatic enzymes/liver failure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Traumatic injuries
Acute patients treated surgically for:
The setting is defined acute when there is less than 24 hours between sustaining the injury and surgery. Elective patients treated surgically for:
|
Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury.
For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time-intensity curves
Time Frame: 1 day
|
The main endpoint of this study is an adequate time-intensity curve extracted from selected regions of interest.
Adequate curves are defined as reproducible curves with accurate representation of the perfusion status.
An adequate curve is characterized by a recognisable in- and outflow pattern representing the bloodflow in the tissue.
Distinguishing between adequate, questionable and inadequate perfusion can only be done after comparing the measurement results.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum intensity (Imax)
Time Frame: 1 day
|
As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include: • Maximum intensity (Imax) in arbitrary units (a.u.) |
1 day
|
|
Time till maximum intensity (Tmax)
Time Frame: 1 day
|
As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include: • Time till maximum intensity (Tmax), in seconds. |
1 day
|
|
The ingress rate and absolute slope
Time Frame: 1 day
|
As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include:
|
1 day
|
|
The normalized slope
Time Frame: 1 day
|
As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include: • The normalized slope in percentages per second (%/s) |
1 day
|
|
The area's under the curve at 30, 60 and 120 seconds
Time Frame: 1 day
|
As secondary study parameters quantified perfusion parameters will be extracted from the time-intensity curves. The parameters extracted include: • Area under the curve at 30, 60 and 120 seconds in percentages (%) |
1 day
|
|
Incidence of necrotic tissue
Time Frame: 90 days of necrotic
|
Perfusion parameters will be evaluated for their correlation with the occurrence of necrotic tissue after initial debridement. This will be calculated as the percentage of people with inadequate perfusion parameters that develop necrotic tissue compared to people with adequate perfused tissue. |
90 days of necrotic
|
|
The amount of additional debridement procedures
Time Frame: 90 days
|
The number of additional debridement procedures when comparing the group with inadequate perfused tissue to the group with adequate perfused tissue. In numbers and percentages. |
90 days
|
|
The infection incidence
Time Frame: 90 days
|
Perfusion parameters will be evaluated for their correlation with the occurrence of wound infection within 90 days after procedure. Infection defined as a red, swollen and painful area that is warm and tender to touch, possibly in combination with fever/chills, purulent effusion, positive cultures or increased infection parameters. The group with adequate perfused tissue will be compared to the group with inadequate perfusion. This will be in numbers and percentages. |
90 days
|
|
The incidence of a fracture related infection
Time Frame: 90 days
|
Incidence of a fracture related infection will be compared between the groups with adequate and inadequate perfusion in numbers and percentages.
|
90 days
|
|
Lentgh of hospital stay
Time Frame: 90 days
|
The length of hospital stay will be measured in days and compared between groups with adequate and inadequate perfusion.
|
90 days
|
|
Amount of readmission
Time Frame: 90 days
|
The number of readmissions within 90 days associated with complications of primary problem (infection, necrosis, death) will be compared between the groups with inadequate and adequate tissue perfusion in numbers and percentages.
|
90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Stefan Koning, MD, Leiden University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL84014.058.23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Perfusion
-
Technical University of MunichUnknown
-
Universitätsklinikum Hamburg-EppendorfRecruitingTissue Perfusion | Microcirculation | Urethral Perfusion IndexGermany
-
University of ZurichTerminatedCT Perfusion and MRI Perfusion in Solid TumorsSwitzerland
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruiting
-
Ain Shams UniversityNot yet recruiting
-
Shanglei LiuRecruitingPerfusion; ComplicationsUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingPerfusion; ComplicationsChina
-
Assiut UniversityRecruiting
-
Assiut UniversityCompleted
Clinical Trials on Near-infrared fluorescence imaging of perfusion
-
Leiden University Medical CenterRecruiting
-
Maastricht University Medical CenterUnknownEndometriosisNetherlands
-
Istanbul UniversityNot yet recruitingOvarian Cancer | Vulvar Cancer | Cervical Cancers | Endometrial Cancers | Gynecologic Cancers | Anastomotic LeaksTurkey
-
Leiden University Medical CenterUnknown
-
University of PittsburghCompletedSolitary Pulmonary NodulesUnited States
-
University of AarhusRigshospitalet, Denmark; InCor Heart Institute; Hospital das Clínicas de Ribeirão...CompletedUniventricular Heart | Lymphatic Abnormalities | Lymphatic EdemaDenmark
-
The University of Texas Health Science Center,...M.D. Anderson Cancer Center; National Cancer Institute (NCI)CompletedLymphedemaUnited States
-
Yonsei UniversityCompleted
-
Saint Petersburg State University, RussiaShandong Linglong Yingcheng Hospital; High-Tech Clinic BeloostrovRecruitingPostoperative Complications | Gastrointestinal Neoplasms | Colorectal Cancer | Anastomosis | Perfusion | Gastric Cancer (GC)China, Russia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); University of TexasCompleted